Pharmacologic agents for smoking cessation: A clinical review by Patel, Dilip R et al.
© 2010 Patel et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Pharmacology: Advances and Applications 2010:2 17–29
Clinical Pharmacology: Advances and Applications
M I N I - R E V I E W
open access to scientific and medical research
Open Access Full Text Article
17
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Pharmacologic agents for smoking cessation:  
A clinical review
Dilip R Patel1 
Cynthia Feucht2 
Lesley Reid1 
Neil D Patel1
1Michigan State University, Kalamazoo 
Center for Medical Studies, 
Kalamazoo, MI, USA; 2Ferris State 
University College of Pharmacy, 
Kalamazoo, MI, USA
Correspondence: Dilip R Patel
Michigan State University, Kalamazoo 
Center for Medical Studies, 1000, Oakland 
Drive, Kalamazoo, MI 49008, USA
Tel +1 269 337 6450
Fax +1 269 337 6475
Email patel@kcms.msu.edu
Abstract: Tobacco use has been clearly demonstrated to have negative health 
  consequences. Smoking cigarettes is the predominant method of tobacco use. The tar con-
tained within cigarettes and other similar products is also harmful. Other tarless tobacco 
containing products do exist but carry no significantly decreased risk. While nicotine is 
considered to be principally responsible for tobacco addiction, other chemicals in the ciga-
rette smoke including acetaldehyde may contribute to the addictive properties of tobacco 
products. The adverse health consequences of tobacco use have been well documented. 
Studies have shown that a combined behavioral and pharmacological approach is more 
effective in smoking cessation than either approach alone. Pharmacotherapy can achieve 
50% reduction in smoking. With pharmacotherapy the estimated 6-month abstinence 
rate is about 20%, whereas it is about 10% without pharmacotherapy. The first-line of 
drugs for smoking cessation are varenicline, bupropion sustained release, and nicotine 
replacement drugs, which are approved for use in adults. Data are insufficient to recom-
mend their use in adolescents. This article reviews the use of pharmacological agents 
used for smoking cessation. A brief overview of epidemiology, chemistry, and adverse 
health effects of smoking is provided.
Keywords: smoking, tobacco, nicotine, nicotine addiction, varenicline, bupropion sustained 
release, nicotine replacement therapy, electronic cigarettes
Introduction
The tobacco plant is native to South America, Mexico, and the West Indies.1 The 
American Indians used various forms of tobacco for its medicinal properties for 
hundreds of years before the discovery of the New World by Christopher Columbus.1 
The common tobacco, Nicotiana tabacum, is named after Jean Nicot, the French 
ambassador to Lisbon, who is believed to have sent its seeds to Catherine de Medi-
cis, the queen consort and regent of France in 1566.1 Nicotine was first extracted 
in its crude form in 1571, purified form in 1928, and synthesized in a laboratory in 
1904.1 Over the decades, the causative role of smoking, and other forms of tobacco 
use, in cancer has been well-established. This article reviews the pharmacological 
agents currently used for smoking cessation. These include the various forms of 
nicotine replacement products, varenicline, bupropion sustained release, nortripty-
line, and clonidine. A brief overview of the epidemiology of smoking, the chemistry 
and pharmacology of nicotine, and adverse health consequences of smoking is 
  provided as a background to better understand the use of pharmacological agents 
for smoking cessation.Clinical Pharmacology: Advances and Applications 2010:2 18
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Epidemiology
Cigarette smoking is the most popular method of using 
tobacco; other forms of smoking and tobacco use are sum-
marized in Table 1.2–4 Worldwide, tobacco use causes more 
than 5 million deaths per year and if the current trends in the 
use of tobacco continue, it will cause 8 million deaths per 
year by 2030.5 Cigarette smoking is the leading preventable 
cause of death in the United States, responsible for about 
one in five or half-million deaths every year.4 Exposure to 
environmental tobacco smoke (ETS) results in an estimated 
49,000 deaths every year.2 Smoking and use of other forms 
of tobacco by youth is of particular significance, with 60% 
of new smokers being under the age of 18 when they first 
smoked a cigarette.
In 2007, more than 3 million American adolescents (aged 
12–17) reported using a tobacco product in the month prior 
to the survey.2 Tobacco use by adolescents is influenced by 
multiple psychosocial and biological factors that increase 
adolescents’ vulnerability for nicotine use.2,6,7 Studies show 
that adolescents are more sensitive to the reinforcing effects 
of nicotine and other chemicals found in cigarettes, further 
increasing their susceptibility to tobacco addiction. Intermit-
tent smoking, such as over the weekends or at parties, has 
also been shown to result in tobacco addiction in adolescents. 
Tobacco use, especially the smokeless forms, is of special 
concern in athletes.8–15
Electronic cigarettes are a new trend and a major concern for 
young smokers.16,17 Electronic cigarettes are marketed to young 
smokers and are easily available over the internet and in shop-
ping malls. The labeling on these cigarettes does not include 
the United States Food and Drug Administration (US FDA) 
warning of its harmful effects.16 Also called e-cigarettes, these 
are battery-operated devices that generally contain cartridges 
filled with nicotine, flavor and other chemicals. The electronic 
cigarette turns nicotine and other chemicals into vapor that 
is inhaled by the user. The US FDA has found that this form 
of cigarette is equally harmful, toxic, and addictive as other 
forms of tobacco use.16,17 In addition to various carcinogens, 
  e-cigarettes also contain other chemicals such as diethylene 
glycol, which is an ingredient found in antifreeze liquid.16
Chemistry and pharmacology
Approximately 4,000 chemicals are found in the smoke of 
tobacco products, of which nicotine is primarily responsible 
for tobacco addiction.2,6,7 The chemistry and neuropharma-
cology of nicotine has been extensively studied.18–21 Other 
Table 1 Main forms of tobacco used
Cigarettes Cigarette brands are categorized based on their tar content: 
Ultra-light 1–6 mg tar 
Light 6–15 mg tar
Full-flavor 15 mg tar 
Of all cigarettes sold in the United States, 84% are either light or ultra-light. Low-yield cigarettes and cigarette-like 
  products are examples of a classification of products referred to as “potentially reduced-exposure products” (PREPs).
Cigars Cigars contain the same toxic and carcinogenic compounds found in cigarettes. The three major types of cigars sold in 
the United States are large cigars, cigarillos, and little cigars.
Bidis Bidis are small, thin hand-rolled cigarettes imported to the United States primarily from India and other Southeast Asian 
countries. They consist of tobacco wrapped in a tendu or temburni leaf (plants native to Asia), and may be secured 
with a colorful string at one or both ends. They have higher concentrations of nicotine, tar, and carbon monoxide than 
conventional cigarettes sold in the United States.
Kreteks Kreteks (clove cigarettes) imported from Indonesia, typically contain a mixture consisting of tobacco, cloves, and other 
additives. Kreteks deliver more nicotine, carbon monoxide, and tar than conventional cigarettes.
Smokeless tobacco Chewing tobacco comes in the form of loose leaf, plug, or twist. Snuff is finely ground tobacco that can be dry, moist, or 
in sachets (tea bag-like pouches). Although some forms of snuff can be used by sniffing or inhaling into the nose, most 
smokeless tobacco users place the product in their cheek or between their gum and cheek. Users then suck on the 
tobacco and spit out the tobacco juices, which is why smokeless tobacco is often referred to as spit or spitting tobacco.
Betel quid with tobacco 
(Gutka)
Gutka (ghutka or gutkha) is a dry, relatively nonperishable commercial preparation that consists of betel leaf 
(Piper betle), tobacco, areca nut (Areca catechu), catechu (extract of the Acacia catechu tree), and slaked lime (calcium 
  hydroxide). Gutka is available in sachets and tins. It is consumed by placing a pinch of the mixture in the mouth between 
the gum and cheek and gently sucking and chewing. The excess saliva produced by chewing may be swallowed or spit 
out. Gutka is primarily consumed in the Indian subcontinent (India, Pakistan, and Bangladesh).
In the Indian subcontinent, nonperishable, commercially manufactured preparations of betel quid without tobacco are 
known as pan masala, and freshly prepared betel quid (with or without tobacco) is known as pan.
Based on data from: Centers for Disease Control and Prevention. Smoking and tobacco use: fact sheets. Available at http://www.cdc.gov/tobacco/data_statistics/fact_sheets. 
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main constituents of smoke that result in adverse health 
consequences include ammonia, benzene, carbon monox-
ide, cyanide, formaldehyde, acetaldehyde, phenols, and tar. 
Approximately 90% of the constituents of the smoke are 
in the form of vaporized chemicals, while rest are in the 
particulate form.2,4,22
Cigarettes are categorized (Table 1) based on their tar con-
tent (total particulate matter in smoke, excluding water and 
alkaloid compounds), which is measured using a standardized 
protocol on a smoking machine.2–4 In filtered cigarettes (99% 
of cigarettes currently on the market), the filter vents dilute 
the smoke with air, reducing standard yields of tar, nicotine, 
and carbon monoxide. Many smokers block the vents or 
compensate with increased inhalations when smoking low-
yield cigarettes. By doing so, they typically get as much tar 
and nicotine from cigarettes with low-yield ratings as those 
with higher yields. On average a cigarette contains between 
13–19 mg of nicotine; smoking 1 cigarette typically deliv-
ers 1–2 mg of nicotine.2,6,7 The nicotine content of tobacco 
smoke is 1%–2% and each inhalation delivers approximately 
0.05–0.15 mg.2,7
Smoke is produced by the incomplete combustion 
of tobacco. The fate of the cigarette smoke is depicted 
in Figure 1.22 Mainstream smoke–the smoke inhaled 
by the smoker directly through the mouthpiece of the 
cigarette–constitutes approximately 45% of the total smoke; 
whereas side stream smoke, which is the smoke emitted by 
smoldering tobacco between puffs and the smoke diffusing 
through the lit cigarette paper and escaping from the burning 
cone during smoking, constitutes 55% of the total smoke.22
Nicotine, whose chemical structure resembles that of the 
neurotransmitter acetylcholine, acts on stereospecific nico-
tinic cholinergic receptors (nAChRs) in the brain and other 
organs.7,21 The chemical structure and metabolic pathway of 
nicotine is depicted in Figure 2. It also has both direct and 
indirect effects on the neuroendocrine system. The initial 
phase of stimulation of the central nervous system (CNS) by 
nicotine is typically followed by a phase of CNS depression.7,20 
The action of nicotine on nAChRs stimulates the release of 
various neurotransmitters and hormones including acetyl-
choline, norepinephrine, dopamine, vasopressin, serotonin, 
and beta-endorphins.2,6,7,19 Research shows that smoking is 
associated with a marked decrease in monoamine oxidase 
(MAO) levels in the brain.7 It is postulated that this decrease in 
MAO is caused by chemicals in the smoke other than nicotine. 
Decreased levels of MAO-A and MAO-B in the brain result in 
a higher level of dopamine. The action of nicotine on the CNS 
increases alertness, improves memory, improves concentra-
tion, and decreases anxiety. The pharmacokinetic properties 
of nicotine are summarized in Table 2.2,4,7,8,21
Effects on health
The wide-ranging adverse effects of tobacco use have been 
well-established and well-documented.2,4,6,22–28 The numerous 
harmful health consequences of smoking are summarized 
in Table 3.
1. Cigarette constituents
•  Organic matter
•  Nicotinic alkyloids
•  Additives
2. Pyrolysis products
Tobacco comprises:
•  Carbon dioxide
•  Carbon monoxide
Smoke
production
by pyrolysis
(1600–1800°F)
Air dilution
and cooling via
porous paper
Mainstream smoke
Filter
traps some
particulates
•  Tar
To lungs, where
absorption occurs
Absorption factors:
•  Inhalation amount
•  Inhalation depth
•  Inhalation duration
•  pH of smoke
•  Absorption characteristics
    of individual constituents
Mainstream smoke
Sidestream smoke
Figure 1 Fate of cigarette smoke.
From: US Department of Health and Human Services: The Health Consequences of Smoking. Nicotine Addiction: A Report of the Surgeon General. Washington, DC, 1988.Clinical Pharmacology: Advances and Applications 2010:2 20
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Nicotine activates reward pathways in the brain that 
regulate feelings of pleasure.7 These effects of nicotine are 
mediated by dopamine. Nicotine increases levels of dopamine 
mainly by its action on the mesolimbic dopamine system.7,21 
Chronic use of nicotine results in an increase in the number 
of nicotine receptors in the brain.6,7,19 Consequently, more 
nicotine is required to achieve the desired effect, eventually 
resulting in tolerance and dependence. Regular tobacco use 
results in nicotine accumulation in the body, exposing the user 
to the effects of nicotine throughout the 24 hours. Nicotine 
levels in the brain and the associated feelings of pleasure and 
reward peak within 10 seconds of inhalation.2,4,7 However, 
the acute effects of nicotine dissipate rapidly. This causes the 
smoker to continue to smoke to maintain the effects of the 
nicotine and prevent withdrawal symptoms. The significant 
neurochemical changes in the brain that result from chronic 
nicotine use make it very difficult for the smoker to quit. 
Animal studies have shown that acetaldehyde, a chemical 
found in tobacco smoke, dramatically increases the reinforc-
ing properties of nicotine and may also contribute to tobacco 
addiction.2,4,7 Adolescent animals show far more sensitivity 
to this reinforcing effect, suggesting increased vulnerability 
of adolescents to tobacco addiction.
Abrupt cessation of smoking results in withdrawal symp-
toms primarily due to decreased nicotine levels. Symptoms of 
nicotine withdrawal include: irritability; craving; depression; 
anxiety; cognitive and attention deficits; sleep disturbances; 
and increased appetite.6,22 The withdrawal symptoms, in most 
cases, begin within a few hours after the last cigarette, peak 
within the first few days of smoking cessation, and usually 
subside within a few weeks. In some cases, however the 
symptoms may persist for months.4,6
The role of behavioral approaches 
to smoking cessation
Behavioral treatment is integral to smoking cessation – studies 
have shown that a combination of behavioral and pharma-
cological treatment is more effective than either approach 
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Figure 2 Chemical structure and metabolic pathway of nicotine.
From: US Department of Health and Human Services: The Health Consequences of Smoking. Nicotine Addiction: A Report of the Surgeon General. Washington, DC, 1988.
Table 2 Pharmacokinetics of nicotine2,4,7,8,21
Absorption •    10%–50% of available nicotine is absorbed during 
puffing; 80% during deep inhalation
•    Readily and completely absorbed via mucous 
  membranes and skin
Distribution •  Readily distributed in all body tissues 
•  Reaches brain within 10 s
• Acute spike in arterial nicotine level occurs
•    Steady state volume of distribution is 
 approximately 2.6 times the body weight in kg
Metabolism •    80% is metabolized in the liver to continine 
by enzyme CYP2A6 (and to a lesser extent by 
CYP2B6 and CYP2E1)
•  Rest is metabolized in the lungs and kidneys
Elimination • Average elimination half-life is 2 h
•   Average elimination half-life of nicotine metabolite 
cotinine is 16 h
•    Cotinine is not detectable in urine after complete 
abstinence of 1 wk
•    Unaltered nicotine and its metabolites excreted 
by kidneysClinical Pharmacology: Advances and Applications 2010:2 21
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Table 3 Adverse health effects of smoking and tobacco use
Disease
Cancer • Bladder cancer
• Cervical cancer
• Esophageal cancer
• Kidney cancer
• Laryngeal cancer
• Leukemia
• Lung cancer
• Oral cancer
• Pancreatic cancer
• Stomach cancer
Cardiovascular diseases • Abdominal aortic aneurysm
•   Acute and episodic increase in blood 
pressure
•   Acute increase in peripheral vascular 
resistance and blood pressure
• Atherosclerosis
• Cerebrovascular disease
• Coronary heart disease
•   Decreased coronary blood flow (due 
to constriction of coronary arteries) 
•   Decreased oxygen carrying capacity 
of the hemoglobin
• Hypertension
• Increased baseline heart rate
•   Increased oxygen demands of the 
  myocardium (due to increased heart 
rate and blood pressure) 
•   Increased risk for thromboembolism
•   Increased risk of ventricular 
  arrhythmias and sudden death (due 
to increased platelet adhesiveness, 
releasing catecholamines causing 
acute thrombosis and promoting 
ventricular arrhythmias)
• Peripheral vascular disease
Respiratory diseases • Bronchiolitis
• Bronchitis 
• Chronic cough
•   Chronic obstructive pulmonary 
disease 
•   Decreased forced expiratory volume 
(FEV1) 
•   Decreased peak expiratory flow rate 
(PEFR)
•   Development and exacerbation of 
asthma
• Dyspnea
• Eosinophilic granuloma
• Halitosis
• Hoarseness
• Idiopathic pulmonary fibrosis
• Impaired lung growth
• Impaired respiratory immunity
• Increased respiratory allergies
• Interstitial lung disease
• Laryngitis
•   Otitis media and middle ear effusions
Table 3 (Continued )
Disease
• Pneumonia
• Pulmonary hemorrhage
• Pulmonary hypertension
• Rhinitis
• Sinusitis
• Snoring
• Spontaneous pneumothorax
• Upper respiratory infections
Reproductive effects • Fertility
• Fetal death and stillbirths
• Low birth weight
• Pregnancy complications
• Premature menopause
Musculoskeletal • Decreased bone mineral density
• Increased risk for fractures
• Increased spinal disk disease
Gastrointestinal • Decreased appetite
• Gastroesophageal reflux disease
• Impaired glucose tolerance
• Increase insulin resistance
• Peptic ulcer disease
Mental health and  
psychosocial
• Addiction
• Anxiety, palpitations, tremors
• Nervousness, depression
• Tolerance and dependence
• Withdrawal symptoms
Effects on offspring  
of maternal smoking  
during pregnancy
• Certain childhood cancers
•   Increased cotinine in breastfed infants 
if mother smokes
•   Increased incidence of conduct 
disorders
•   Increased probability of female chil-
dren to be smokers
• Low birth weight
• Miscarriage
• Prematurity
• Sudden infant death syndrome
Specific effects of  
smokeless tobacco use
• Excess salivation
• Gingivitis, gingival recession
• Halitosis
• Leukoplakia
• Oropharyngeal cancers
• Periodontal disease
• Staining of teeth
Other effects • Altered lipid profile
•    Altered metabolism of therapeutic 
drugs
• Anorexia and weight loss
• Cataracts
• Decreased exercise performance
•   Diminished health status/increased 
morbidity
• Esophagitis
• Gastroesophageal reflux disease
• Hip fractures
• Low bone density
(Continued) (Continued)Clinical Pharmacology: Advances and Applications 2010:2 22
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alone.3,29–32 Fiore and colleagues provide an extensive analysis 
of scientific evidence supporting the optimal efficacy of the 
combined behavioral and pharmacological approach for 
smoking cessation. The results of their meta-analysis of pub-
lished studies indicate that providing counseling in addition 
to medication significantly enhanced treatment outcome – for 
medication alone the odds ratio (95% confidence interval 
[CI]) was 1.0, and estimated abstinence rate (95% CI) was 
21.7, whereas for medication and counseling the estimated 
odds ratio (95% CI) was 1.4 (1.2–1.6), and estimated absti-
nence rate (95% CI) was 27.6 (25.0–30.3).3 Conversely, 
Fiore and colleagues also found that providing medication in 
addition to counseling also significantly enhanced treatment 
  outcome – for counseling alone the estimated odds ratio (95% 
CI) was 1, and estimated abstinence rate (95% CI) was 14.6, 
whereas for medication and counseling the estimated odds 
ratio (95% CI) was 1.7 (1.3–2.1) and the estimated abstinence 
rate (955 CI) was 22.1 (18.1–26.8).3
In addition to the neurochemical effects of nicotine, 
behavioral factors also affect the severity of nictotine with-
drawal symptoms. For some people, the feel, smell, and sight 
of a cigarette and the ritual of obtaining, handling, lighting, 
and smoking a cigarette are all associated with the pleasur-
able effects of smoking. Consequently, this can worsen 
withdrawal symptoms or cravings. Behavioral therapies can 
help smokers identify environmental triggers of craving so 
they can employ strategies to prevent or circumvent these 
symptoms and urges. It is important to recognize that smok-
ing cessation is a team effort. The social setting in which 
smoking occurs, the social culture of the smoker, and the sup-
port networks available to the smoker, all play critical role in 
the success of smoking cessation by the smoker. Among the 
professionals, the pharmacist plays a critical role in providing 
ongoing support, education, and counseling.
Pharmacological agents
General factors, which should to be considered when 
  prescribing pharmacological agents for smoking cessation, 
are summarized in Table 4. Patients who smoke may be on 
therapeutic drugs for other chronic diseases. The effective 
dosages of these therapeutic drugs reflect the adjustments 
made because of concomitant exposure to nicotine. With 
smoking cessation and elimination of nicotine from the 
body, a new state of metabolic homeostasis will result that 
may necessitate adjusting dosage of therapeutic drugs. 
Drug-drug interactions are an important consideration when 
using pharmacotherapy for smoking cessation, especially in 
smokers who are on other medications for chronic diseases. 
Smoking induces some isoforms of the hepatic cytochrome 
P450.3 Nicotine, although metabolized by CYPP2A6, is not 
a significant inducer of CYP enzymes.3 Therefore, when 
smoker quits with or without being on nicotine replacement 
therapy, the baseline functioning of the P450 enzyme system 
is restored, and can increase the serum levels of certain drugs 
(eg, fluvoxamine, olanzepine, clozapine), resulting in their 
increased side-effects.3 Nicotine replacement therapy may 
reduce the sedative effects of benzodiazepines, subcutane-
ous absorption of insulin, and the blood pressure lowering 
effect of some beta-blockers.3 Some drugs reported to have 
significant interactions with bupropion include: cyclophos-
phamide; orphenadrine; tricyclic antidepressants; antipsy-
chotics; certain antiarrhythmic drugs; certain beta-blockers; 
carbamazepine; phenytoin; phenobarbital; valproate; and 
cimetidine.3 Varenicline is not reported to have specific 
significant drug-drug interactions.
Tobacco dependence should be considered a chronic dis-
ease and as such its management requires on-going patient 
education, counseling, and use of medications as indicated.3 
Relapses are common during smoking cessation and patients 
require long-term monitoring and treatment. Long-term 
pharmacotherapy, combination therapy, and re-use of drugs 
previously used (recycling) should be considered in relapse 
prevention and treatment. In some patients who are not able 
to quit completely, pharmacotherapy has been used to reduce 
smoking, with some achieving a 50% reduction in smoking.3,7 
With pharmacotherapy, the estimated 6-month abstinence rate 
is about 20%, compared to approximately 10% without phar-
macotherapy.3,6,7 All pharmacologic agents have been shown 
to be effective in smoking cessation with odds ratios between 
two and four when compared to placebo treatment.3,6 Absolute 
smoking cessation rates vary depending on the particular phar-
macologic agent used and the intensity of concomitant coun-
seling; rates vary in range from 5% to 35%.3,6,7 The smoker’s 
Table 3 (Continued)
Disease
•   Macular degeneration 
•   Nicotine addiction (tolerance 
  dependence, withdrawal symptoms)
• Osteoporosis
• Peptic ulcer disease
• Spinal disk disease
Sources: U.S. Department of Health Education, and Welfare 1964, 1967, 1979; U.S. 
Department of Health and Human Services 1980, 1982, 1983, 1984, 1989, 1990, 
1994, 2001. Data from: (1) U.S. Department of Health and Human Services: The 
Health Consequences of Smoking. Nicotine Addiction: A Report of the Surgeon 
General. Washington, DC, 1988 U.S. Department of Health and Human Services;   
(2) The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, 
GA: U.S. Department of Health and Human Services, CDC, National Center for 
Chronic Disease Prevention and Health Promotion, Office of Smoking and Health, 
2004. Available at http://www.cdc,gov/tobacco/data_statistics/sgr_2004/index.htm. 
Accessed August 11, 2009.Clinical Pharmacology: Advances and Applications 2010:2 23
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likelihood of long-term abstinence doubles with the use of 
nicotine inhaler, nicotine lozenge, nicotine nasal spray, or 
nicotine patch.3 Smith and colleagues looked at comparative 
effectiveness of 5 smoking cessation pharmacotherapies in 
primary care clinics. They reported 6 month abstinence rates 
for the 5 active pharmacotherapies as follows: bupropion 
SR, 16.8%; lozenge, 19.9%; patch, 17.7%; patch + lozenge, 
26.9%; and bupropion SR + lozenge, 29.9%.29 In a recent 
study Garrison and Dugan reported a quit rate for varenicline 
that ranged from approximately 40% to 65%.31
The first-line drugs for smoking cessation approved by 
the US Food and Drug Administration (FDA) are varenicline, 
bupropion sustained release (SR), and nicotine replacement 
drugs.3,33–44 These drugs are approved by the FDA for use 
in adults. Data are insufficient to assess their efficacy in 
adolescents.3 Pharmacotherapy has not been shown to be 
effective in light smokers and in those who use smokeless 
tobacco.
Varenicline
Varenicline acts by selective binding at α4β2 neuronal 
  nicotinic acetylcholine receptors, which results in agonist 
activity, while simultaneously preventing nicotine bind-
ing to α4β2 receptors.7,39–41 The FDA recommendation for 
varenicline product label includes a warning that serious 
neuropsychiatric symptoms have been reported in patients 
being treated with this drug. Varenicline, therefore, should 
preferably be avoided in persons who have a history of neu-
ropsychiatric disorders. It is not uncommon for patients to 
experience feelings of depression, anxiety, irritability, and 
sleep disturbances during smoking cessation. Although some 
of these symptoms may be associated with nicotine with-
drawal, symptoms have occurred in patients who continued 
to smoke. Patients on varenicline should be monitored for 
agitation, depressed mood, and changes in behavior that are 
not typical for the patient. The patient also must be assessed 
for suicidal ideation or suicidal behavior. Varenicline is 
Table 4 Factors to be considered in the use of smoking cessation drugs
Practical considerations Health insurance coverage, out-of-pocket costs, likelihood of adherence, dentures when considering the gums, or 
  dermatitis when considering the patch.
Patient’s prior experience  
with a medication
Prior successful experience (sustained abstinence with the medication) suggests that the medication may be helpful 
to the patient in a subsequent quit attempt, especially if the patient found the medication to be tolerable and or easy 
to use. However, it is difficult to draw firm conclusions from prior failure with a medication.
Environmental factors Consider the importance of smoker’s social setting, social culture, and support networks. These and other environ-
mental factors play important role in the success of any smoking cessation strategy.
Heavy users or smokers The higher-dose preparations of nicotine gum, patch, and lozenge have been shown to be effective in highly 
  dependent smokers. Combination nicotine replacement therapy (NRT) may be particularly effective in suppressing 
tobacco withdrawal symptoms. NRT combinations are especially helpful for highly dependent smokers or those with 
a history of severe withdrawal.
Light users or smokers Cessation medications generally not beneficial to light smokers. If NRT is used with light smokers, consider reducing 
the dose of the medication. No adjustments are necessary when using bupropion SR or varenicline.
Gender NRT can be effective with both sexes; however, evidence is mixed as to whether NRT is less effective in women than 
men. This may encourage the clinician to consider use of another type of medication with women, such as bupropion 
SR or varenicline.
Weight gain concern Bupropion SR and nicotine replacement therapies, in particular 4-mg nicotine gum and 4-mg nicotine lozenge,  
delay – but do not prevent – weight gain.
Depression Bupropion SR and nortriptyline appear to be effective, but nicotine replacement medications also appear to help 
  individuals with a history of depression.
History of cardiovascular  
disease
The nicotine patch has been demonstrated safe for patients with a history of cardiovascular disease.
Long-term use Long-term use is helpful with smokers who report persistent withdrawal symptoms during the course of medications, 
who have relapsed in the past after stopping medication, or who desire long-term therapy. A minority of individuals 
who successfully quit smoking use ad libitum NRT medications (gum, nasal spray, inhaler) long-term. The use of these 
medications for up to 6 months does not present a known health risk and developing dependence on medications is 
uncommon. The FDA has approved the use of bupropion SR, varenicline, and some NRT medications for 6-month use.
Combination therapy Combining the nicotine patch long-term (14 weeks) with nicotine gum or nicotine nasal spray, the nicotine patch 
with the nicotine inhaler, or the nicotine patch with bupropion SR, increases long-term abstinence rates relative to 
placebo treatments. Combining varenicline with NRT agents has been associated with higher rates of side effects  
(eg, nausea, headaches).
Sources: Copyright © 2008. Modified with permission from: Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence 2008 Update. Clinical Practice Guideline. 
Rockville, MD: U.S. Department of Health and Human Services. Public Health Service, 2008.Clinical Pharmacology: Advances and Applications 2010:2 24
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reported to be well-tolerated for up to 1 year and may reduce 
the incidence of relapse.41 Prescribing information for var-
enicline is summarized in Table 5.
Bupropion sustained release (SR)
The proposed mechanisms of action of bupropion sustained 
release (SR) include the blockade of neuronal re-uptake of dopa-
mine and norepinephrine.42 Similar to varenicline, bupropion SR 
also carries an FDA warning for neuropsychiatric adverse events. 
Bupropion lowers the seizure threshold and is contraindicated 
in persons with a history of seizure disorder and those who are 
on other medications that lower the seizure threshold.3 It is also 
contraindicated in persons who have a prior or current history of 
eating disorder because of an increased risk for seizures.3 Bupro-
pion SR is also an anti-depressant and like other anti-depressant 
drugs, it carries a warning for increased risk of suicidal ideation. 
Patients on bupropion should therefore be closely monitored 
for emerging neuropsychiatric symptoms and signs of suicidal 
ideation. Prescribing information for bupropion SR for smoking 
cessation is summarized in Table 6.
Table 5 VareniclineRx
Product Chantix® (Pfizer, Inc., New York City, NY)
• 0.5 mg, 1 mg tablet
Precautions • Pregnancy
• May worsen pre-existing psychiatric illness
•   Dosage adjustment required in patients with kidney 
disease (creatinine clearance less than 30 ml/min) or 
who are on dialysis
•   WARNING: Can cause depressed mood, agita-
tion, change in behavior, suicidal ideation, suicide. 
Reported in patients attempting to quit smoking 
while using varenicline. Monitor closely.
Dosage Recommended: 1-week titration:
Days 1–3: 0.5 mg tablet daily
Days 4–7: 0.5 mg tablet BID (AM and HS)
Days 8+: 1 mg tablet BID (AM and HS)
• Set quit date
• Start one week before quit date
• Take after eating and with a full glass of water
•   Nausea is dose related; if persistent and trou-
bling, consider dose reduction. Duration: 12 wk; 
if successful after 12 week, an additional 12 week 
is recommended for increased likelihood of 
long-term abstinence
Side effects • Dose dependent nausea (most common)
• Insomnia
• Abnormal dreams
• Headache
• Dyspepsia
• Constipation
• Flatulence
• Vomiting
Advantages •   Provides nicotine effects to reduce withdrawal 
symptoms and cravings
•   Blocks the nicotine effects from smoking and 
reduces reward of smoking
• May be used in those with cardiovascular disease
• No clinically meaningful drug interactions
• Found to be more effective than bupropion SR
Disadvantages 
 
 
 
 
 
 
• Not studied in combination with other therapies
•   Nausea associated with higher doses may be  
bothersome
• Does not reduce weight gain
•   May cause impaired ability to drive or operate heavy 
machinery
•   May cause neuropsychiatric symptoms including 
behavioral changes, agitation, depressed mood, 
suicidal ideation, and suicidal behavior
Table 6 Bupropion SRRx
Product Zyban® (GlaxoSmithKline plc, Brentford, London, 
England, UK), Generic
• 150 mg sustained-release tablet
Contraindications • History of seizure disorder
• History of stroke
•   History of brain tumor, brain surgery, or serious 
closed head injury
• Eating disorders
• Those taking another form of bupropion
•   Monoamine oxidase inhibitor therapy within 
previous 14 d
•   Abrupt discontinuation of alcohol or 
benzodiazepines at same time
Precautions • Pregnancy
•   Concomitant therapy with medications known to 
lower the seizure threshold
Dosage 150 mg PO q AM × 3 d, then increase to 150 mg 
PO BID
•   Treatment should be initiated while patient is 
still smoking
• Set quit date 1–2 weeks after initiation
• DO NOT exceed 300 mg/d 
• Allow at least 8 h between doses
• Avoid bedtime dosing to minimize insomnia
• Can be used safely with NRT
•   If progression towards abstinence unsuccessful 
by week 7, discontinue
Duration: 8–12 wk, maintenance up to 6 months
Side effects • Insomnia most common (35%–40%)
• Dry mouth
• Nervousness
• Agitation
• Anxiety
• Weight loss
• Constipation
• Seizures (risk is 1/1000)
Advantages • Bupropion can be safely used with NRT
•   Bupropion may be beneficial in patients with 
depression
• No tapering required
Disadvantages • Seizure risk is increased
•   May increase the risk of suicidal thinking in 
patients who have depressionClinical Pharmacology: Advances and Applications 2010:2 25
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Nicotine replacement therapies
Nicotine replacement therapy (NRT) drugs reduce craving 
and withdrawal symptoms by partially replacing lost nicotine 
intake. The main characteristics and prescribing informa-
tion of available NRT products are summarized in Tables 7 
through Table 11.3,29,33–35,43,44
Second-line medications
Clonidine and nortriptyline are second-line medications 
used for smoking cessation.3,45 Although second-line 
medications have been shown to be effective in treating 
tobacco dependence, their use is limited mainly because 
of less favorable side-effect profile when compared to the 
first-line medications. Second-line medications are not 
approved by the FDA specifically for use in smoking cessa-
tion.3 Second-line medications should be considered for use 
on a case-by-case basis after first-line medications (either 
alone or in combination) have been used without success, 
or are contraindicated.3
Clonidine is contraindicated in pregnant women and in 
those who engage in potentially hazardous activities. The 
most common side effects of clonidine include dry mouth 
(40%), drowsiness (33%), dizziness (16%), sedation (10%) 
and constipation (10%).3 Because abrupt discontinuation of 
clonidine can result in severe rebound hypertension, it should 
be tapered. Clonidine is available as 0.1 mg, 0.2 mg, and 
0.3 mg scored tablets and 0.1 mg/24 hours, 0.2 mg/24 hours, 
and 0.3 mg/24 hours transdermal patches. The usual dosage is 
0.2 mg–0.6 mg per day in divided doses.3,45 Specific dosage of 
clonidine for smoking cessation has not been established.
Nortriptyline is a tricyclic antidepressant and therefore 
carries an FDA warning about increased suicide risk.3 The 
most serious side effects of nortriptyline are arrhythmias 
and impairment of myocardial contractility. More common 
and less serious side effects include sedation, dry mouth, 
blurred vision, urinary retention, lightheadedness, and shaky 
hands.3 Nortriptyline is available as 10 mg, 25 mg, 50 mg, 
and 75 mg capsules and 10 mg/5 mL liquid. The dosage of 
Table 7 Transdermal PreparationsOTC/Rx
Products Nicotrol Patch® (McNeil Consumer Healthcare,  
Fort Washington, PA)
• 5 mg
• 10 mg, 15 mg (16 hours)
Nicoderm® CQ (Sanofi-Aventis S.A., Paris, 
France); Generic nicotine patch
•  7 mg
•  14 mg, 21 mg (24 hours)
Dosage 10 cigarettes/day •  15 mg/day × 6 week
•  10 mg/day × 2 week
•  5 mg/day × 2 week
•  21 mg/day × 6 week
•  14 mg/day × 2 week
•  7 mg/day × 2 weeks
10 cigarettes/day •  10 mg/day × 6 week 
•  5 mg/day × 2 week
•  14 mg/day × 6 week
•  7 mg/day × 2 week
•  If 100 lbs or cardiovascular disease: 
•  14 mg/day × 4–6 week
•  7mg/day × 2–4 week
Commentsa •  Remove before bedtime
•  Nicotine released over 16 h
•  May wear patch for 24 h
•    Remove at bedtime if patient experiences sleep 
disturbances.
Contraindications •  Pregnancy
•  Recent (2 or less week post-myocardial infarction) 
•  Unstable angina pectoris
•  Serious underlying arrhythmias
Side effects •  Local skin reactions: erythema, pruritis, burning
•  Headache
•  Sleep disturbances: insomnia, vivid dreams
Advantages •  Provides consistent nicotine levels over 16–24 hours
•  Easy to use and conceal
•  Fewer adherence issues
• Available without prescription
Disadvantages •  Patients cannot titrate the dose
• Allergic reactions to adhesive
•  Patients with certain skin conditions cannot use patch
•  Patch may contain aluminum
Notes: aPatch should be applied in the morning when patient wakes on the quit day. Apply on relatively hairless areas between the neck and waist.Clinical Pharmacology: Advances and Applications 2010:2 26
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Table 8 GumOTC
Product Nicorette® (GlaxoSmithKline plc, Brentford, 
London, England, UK), Nicorette DS® (GlaxoSmith-
Kline plc, Brentford, London, England, UK), Generic
• 2 mg, 4 mg; regular, mint, orange
Contraindications • Pregnancy
• Recent (2 weeks) myocardial infarction
• Serious underlying arrhythmias
• Serious or worsening angina pectoris
• Temporomandibular joint disease
Dosage 25 cigarettes/day: 4 mg
25 cigarettes/day: 2 mg
  Week 1–6: 1 piece q 1–2 hours
  Week 2–4: 1 piece q 2–4 hours
  Week 10–12: 1 piece q 4–8 hours
•   Chew each piece slowly until peppery or 
flavored taste emerges
• Park between cheek and gum when tingling 
• sensation appears
• Resume chewing when tingle fades
•   Repeat chew/park steps until most of the nico-
tine is gone (taste or tingle does not return; 
generally 30 minutes)
• Park in different areas of mouth
•   No food or beverages 15 minutes before or 
during use (acidic beverages reduce buccal 
absorption)
•   If there are strong or frequent cravings, may 
use a 2nd piece within the hour 
Max: 24 pieces/day
Duration: Up to 12 week
Side effects • Mouth soreness
• Throat irritation
• Jaw pain
• Hiccups
• Dyspepsia
• Hypersalivation
• Flatulence
• Nausea and vomiting
• Unpleasant taste
• Lightheadedness
Advantages • Might satisfy oral cravings
• May delay weight gain
•   Patients can titrate therapy to manage with-
drawal symptoms
• Available over the counter
Disadvantages • Gum chewing may not be socially acceptable
• Difficult to use with dentures
• May cause loosening of dental fillings
•   Patients must use proper chewing technique to 
minimize adverse effects
nortriptyline in smoking cessation studies ranges between 
25 mg per day and 100 mg per day.3,45,46 Therapeutic drug level 
and cardiovascular monitoring, including electrocardiogram 
(ECG), is recommended.
Several investigators have reported on the use of ion-
tophoresis and chemical enhancers to deliver nortriptyline 
and other smoking cessation agents transdermally. 
Escobar-Chavez and colleagues report that the controlled 
delivery of a chemical through the skin can be achieved by 
constant current iontophoresis.47 This involves the applica-
tion of a small electrical potential and is unique to iontopho-
resis. The amount of compound delivered by iontophoresis 
is directly proportional to the quantity of charge passed, the 
current applied, the duration of current application, and the 
area of the skin surface in contact with the active electrode 
compartment.47 Melero and colleagues reported on results of 
their study on delivery of nortriptyline using iontophoresis.48 
They noted that the highest flux obtained would provide the 
recommended doses for smoking cessation support therapy 
(25–75 mg) with a 2 cm × 2 cm patch or 3.5 cm × 3.5 cm 
patch, respectively, without skin damage.48 Merino and 
Table 9 LozengeOTC
Product Commit® (GlaxoSmithKline plc, Brentford, London, 
England, UK)
• 2 mg, 4 mg
Contraindications • Pregnancy
• Recent (2 weeks) myocardial infarction
• Serious underlying arrhythmias
• Serious or worsening angina pectoris
Dosage 1st cigarette 30 min after waking up: 4 mg
1st cigarette 30 min after waking up: 2 mg
Week 1–6: 1 lozenge q 1–2 hours; minimum  
9 per day
Week 7–9: 1 lozenge q 2–4 hours
Week 10–12: 1 lozenge q 4–8 hours
•   Allow lozenge to dissolve slowly  
(20–30 minutes )
•   Nicotine release may cause a warm or tingling 
sensation
•   Do not chew or swallow the lozenge
•   Rotate the lozenge to different areas of the 
mouth
•   No food or beverages 15 minutes before, during 
or after use
•   Do not use more than 1 lozenge at a time
Max: 5 lozenges every 6 h; 20 lozenges/day
Duration: up to 12 week
Adverse events • Nausea
• Hiccups
• Cough
• Heartburn
• Headache
Advantages • Might satisfy oral cravings
• May delay weight gain
•   Patients can titrate therapy to manage 
  withdrawal symptoms
• Provides ∼25% more nicotine than gum
• Available over the counter
Disadvantages • Gastrointestinal side effects might be bothersome
• Contains phenylalanineClinical Pharmacology: Advances and Applications 2010:2 27
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colleagues reported on the use of chemical enhancers and 
ionotphoresis to enhance transdermal delivery of nortripty-
line.49 They also noted that iontophoresis could be used to 
provide therapeutic concentrations of the drug in smoking 
cessation treatment.
Conclusion
Tobacco use remains a great public health concern, especially 
in adolescents. The significant health hazards of smoking and 
other forms of tobacco use are well-documented. Smoking 
can also adversely affect exercise and sports performance. 
Tobacco addiction is primarily caused by nicotine, though 
other chemicals contained within tobacco products are now 
believed to play a secondary role in addiction. A combined 
behavioral and pharmacological approach has been found to 
be more effective for smoking cessation than either approach 
used alone. The importance of team effort in any smoking 
cessation strategy should be recognized. The environmental 
factors and public policies play important roles in popula-
tion wide smoking cessation efforts. Considerable evidence 
supports the role of the pharmacist in the management of 
chronic diseases, including smoking cessation. To decrease 
the overall burden of smoking, all healthcare practitioners 
need to work together. A range of pharmacological agents 
and behavioral therapies are available for smoking cessation. 
Table 11 Oral inhalerRx
Product Nicotrol Inhaler® (Pfizer, Inc., New York City, NY)
•   10 mg cartridge delivers 4 mg inhaled nicotine 
vapor
Contraindications • Pregnancy
• Recent (2 weeks) myocardial infarction
• Serious underlying arrhythmias
• Serious or worsening angina pectoris
Dosage 6–16 cartridges/d; individualize dosing
•   Initially, use at least 6 cartridges/d for first 
3–6 week
•   Best effects with continuous puffing for 
20 minutes
•   Nicotine in cartridge is depleted after 
20 minutes of active puffing (oral inhalation)
•   Patients should inhale deeply into back of throat 
or puff in short breaths
• Open cartridge retains potency for 24 hours
•   Each cartridge delivers 4 mg of nicotine over 80 
inhalations
•   Avoid eating or drinking for 15 minutes 
before and after use (acidic beverages reduce 
 absorption)
Duration: Treat for 3 month and then taper over 
next 3 month
Adverse events • Mouth and throat irritation (40%)
• Unpleasant taste
• Cough (32%)
• Rhinitis (23%)
• Dyspepsia
• Headache
Advantages •   Patients can easily titrate therapy to rapidly man-
age withdrawal symptoms
•   The inhaler mimics hand-to-mouth ritual of 
smoking 
Disadvantages •   Initial throat or mouth irritation can be 
bothersome
• Dependence can occur
•   Cold temperatures (60°F) reduce amount of 
nicotine delivered
•   Avoid hot environments (77°F) and protect 
from light
•   Patients with underlying bronchospastic disease 
must use with caution
• No definitive tapering schedule
• Prescription only
Table 10 Nasal sprayRx
Product Nicotrol NS® (Pfizer, Inc., New York City, NY)
•   Metered spray (0.5 mg nicotine/actuation) aqueous 
nicotine
Contraindications • Pregnancy
• Recent (2 weeks) myocardial infarction
• Serious underlying arrhythmias
• Serious or worsening angina pectoris
Dosage 1–2 doses/h (8–40 doses/day)
One dose: 2 sprays (one in each nostril); each spray 
delivers 0.5 mg of nicotine to the nasal mucosa 
•   Patients should not sniff, swallow, or inhale 
through the nose as the spray is administered
• For best results, initially use at least 8 doses/day
•   DO NOT exceed 5 doses/hours and  
40 doses/ day
• Gradually decrease usage
Duration (maximal): 3 month
Side effects •   Nasal and throat irritation (hot, peppery, or 
  burning sensation)
• Transient change in sense of smell and taste
• Rhinitis
• Tearing
• Sneezing
• Cough
• Headache
• Nausea
Advantages •   Patients can easily titrate therapy to rapidly 
  manage withdrawal symptoms
• Fastest acting nicotine product
Disadvantages • Nasal/throat irritation may be bothersome
• Dependence can result
•   Patients must wait 5 minutes before driving or 
operating heavy machinery
•   Patients with chronic nasal disorders (allergy, 
rhinitis, nasal polyps, or sinusitis) or severe reactive 
airway disease should NOT use the spray
• No optimal tapering schedule
• Prescription onlyClinical Pharmacology: Advances and Applications 2010:2 28
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Varenicline, bupropion SR, and nicotine replacement 
therapies are recommended as first-line drugs for smoking 
cessation. In selected cases the first-line drugs may also be 
used in combination with each other to improve outcomes. 
Treatment interventions have been shown to double the rate 
of smoking cessation when compared to quit attempts without 
intervention. Tobacco dependence should be considered a 
chronic disease with anticipated relapses requiring long-term 
monitoring and treatment.
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